Objective: The Flow Cytometry Shared Resource (FCSR) supports translational and clinical cancer research projects of University of Colorado Cancer Center (UCCC) members with flow cytometric analysis, high-speed cell sorting, microscopy, and multiplexed fluorescent microsphere assays. Services and Technologies: FCSR provides a wide range of assays particulariy pertinent to cancer research, including cell cycle, cell proliferation, apoptosis, cell viability, cell signaling, stem cell detection, fluorescent protein analysis, and cell phenotyping along with cell sorting. Housing 4 high-speed sorters, 8 color analyzers, 1 Luminex system, 1 cell counter, 1 imaging cytometer, 6 microscopes, and 1 confocal scanning system, FCSR has 5,000 and 13,500 hours/year of cell sorting and analysis capacity, respectively;1,500 hours/year of Luminex capacity;and 12,000 hours/year of microscope-based research capacity. Consultation and Training: FCSR provides a consultation to help those members with little flow cytometry or immunology background to design appropriate experiments. In addition, regular training sessions are held to inform UCCC members and the investigators in their laboratories of new techniques and FCSR capabilities. Many investigators also call FCSR on an ad hoc basis for advice on performing experiments. Utilization: FCSR is among the most popular and most highly used of the UCCC shared resources. More than 100 different Cancer Center members from 6 programs and 7 consortium institutions use either the UCD or the NJH branch facilities. Management and Finances: This resource is UCCC-managed. Currently, 7 1% of the operating budget comes from charge backs to UCCC members who represent 76% of Shared Resource users. FCSR requests $220,370 CCSG support for 2 1% of its operating budget Increased funding will expand assay capabilities and will maintain the FCSR's place at the forefront of cytometry technology as the first Beckman Coulter Cytometry Center of Excellence.

Public Health Relevance

Using flow cytometric analysis, high-speed cell sorting, microscopy, and multiplexed fluorescent microsphere assays, the Flow Cytometry Shared Resource can perform a wide range of assays supporting cancer research, including cell cycle, cell proliferation, apoptosis, cell viability, cell signaling, stem cell detection, fluorescent protein analysis, and cell phenotyping. These assays are crucial to understanding how cancer derails normal cellular processes to cause disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-25
Application #
8567555
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$98,464
Indirect Cost
$32,305
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Lee-Sherick, Alisa B; Jacobsen, Kristen M; Henry, Curtis J et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1634 publications